

BOLDRON et al.
U.S. National Phase of PCT/EP2004/004016

AMENDMENTS TO THE ABSTRACT

Please insert the Abstract of the Disclosure which is on the attached sheet.

ABSTRACT OF THE DISCLOSURE

The invention relates to the use of nitrogeneous polycyclic derivatives for preparing drugs for treating neurodegenerative diseases, said derivatives having formula : (I) wherein R_n is R_1 , R_2 , R_3 and R_4 , identical or different and represent H or one or several radicals selected in the group comprising -OH, alkyl, -O-alkyl, -NH₂, -NH-alkyl, -N (R_5 , R_6), the alkyl being a C1-C6 alkyl, or an halogen, - Y forms a phenyl with both pyridines, optionally ortho-substituted by R_5 , or ortho-disubstituted by R_5 and R_6 , said substituents, identical or different, being selected amongst alkyl, -O-alkyl, -NH₂, -NH-alkyl, -N (R_5 , R_6), the alkyl being a C1-C6 alkyl, or an halogen, or represents $-(CH_2)_{m1}-W-(CH_2)_{m2}$, with M_1 and M_2 being 0, 1 or 2, and W being a group -CH₂-, -CH-(R_7), O, or N (R_8 , R_9), R_7 , R_8 and R_9 , identical or different, being a C1-C3 alkyl radical, or H, - Z is $-A-(CH_2)_m-U-(CH_2)_n-A-$, with A = O or N, and U = $-(CH_2)_n$ -, -N(R_1 , R_2), -COOH, -OH, with n is 2 to 6, and n_1 is 0 or 1, and the complexes thereof with transition metals.